Cost effectiveness of tinzaparin sodium versus unfractionated heparin in the treatment of proximal deep vein thrombosis. (Q53424803)

14 May 2018

title

Cost effectiveness of tinzaparin sodium versus unfractionated heparin in the treatment of proximal deep vein thrombosis. (English)

1 reference

14 May 2018

0 references

1 reference

J Jaime Caro

1

1 reference

14 May 2018

Denis Getsios

series ordinal

2

1 reference

14 May 2018

Ingrid Caro

series ordinal

3

1 reference

14 May 2018

Judith A O'Brien

series ordinal

4

1 reference

14 May 2018

publication date

1 January 2002

1 reference

14 May 2018

published in

PharmacoEconomics

1 reference

14 May 2018

volume

20

1 reference

14 May 2018

issue

9

1 reference

14 May 2018

page(s)

593-602

1 reference

14 May 2018

https://scigraph.springernature.com/pub.10.2165/00019053-200220090-00003

exact match

0 references

cites work

Guide to anticoagulant therapy. Part 2: Oral anticoagulants. American Heart Association

1 reference

12 December 2020

Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group

1 reference

12 December 2020

Therapeutic application of subcutaneous low-molecular-weight heparin in acute venous thrombosis

1 reference

12 December 2020

Efficacy of a low molecular weight heparin administered intravenously or subcutaneously in comparison with intravenous unfractionated heparin in the treatment of deep venous thrombosis. Certoparin-Study Group.

1 reference

12 December 2020

Venous thromboembolism

1 reference

12 December 2020

Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis

1 reference

12 December 2020

Cost-effectiveness of low-molecular-weight heparin and unfractionated heparin in treatment of deep vein thrombosis

1 reference

12 December 2020

Does this patient have deep vein thrombosis?

1 reference

12 December 2020

Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis

1 reference

12 December 2020

Economic evaluation of outpatient treatment with low-molecular-weight heparin for proximal vein thrombosis

1 reference

12 December 2020

Low-molecular-weight heparins

1 reference

12 December 2020

Direct Medical Cost of Managing Deep Vein Thrombosis According to the Occurrence of Complications

1 reference

12 December 2020

Use of low molecular weight heparin (dalteparin), once daily, for the treatment of deep vein thrombosis. A feasibility and health economic study in an outpatient setting. Swedish Venous Thrombosis Dalteparin Trial Group

1 reference

12 December 2020

Cost of Long-Term Complications of Deep Venous Thrombosis of the Lower Extremities: An Analysis of a Defined Patient Population in Sweden

1 reference

12 December 2020

Automated computer interviews to elicit utilities: potential applications in the treatment of deep venous thrombosis

1 reference

12 December 2020

Comparison of the relative efficacy and safety of low molecular weight heparin and unfractionated heparin for the treatment of deep venous thrombosis

1 reference

12 December 2020

The Long-Term Clinical Course of Acute Deep Venous Thrombosis

1 reference

12 December 2020

Cost effectiveness of the prevention and treatment of deep vein thrombosis and pulmonary embolism

1 reference

12 December 2020

A randomised trial of subcutaneous low molecular weight heparin (CY 216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. A collaborative European multicentre study

1 reference

12 December 2020

A comparison between low molecular weight heparin (KABI 2165) and standard heparin in the intravenous treatment of deep venous thrombosis

1 reference

12 December 2020

Cost-effectiveness of low-molecular-weight heparin in the treatment of proximal deep vein thrombosis

1 reference

12 December 2020

Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis

1 reference

12 December 2020

1 reference

12 December 2020

The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors.

1 reference

12 December 2020

Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin.

1 reference

12 December 2020

Low-molecular-weight heparin in the treatment of patients with venous thromboembolism

1 reference

12 December 2020

Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis

1 reference

12 December 2020

Two daily subcutaneous injections of fragmin as compared with intravenous standard heparin in the treatment of deep venous thrombosis (DVT).

1 reference

12 December 2020

Low molecular weight heparin: a critical analysis of clinical trials

1 reference

12 December 2020

A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire

1 reference

12 December 2020

Patient outcomes and cost analysis associated with an outpatient deep venous thrombosis treatment program

1 reference

12 December 2020

Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin vs intravenous heparin. An economic perspective

1 reference

12 December 2020

Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial

1 reference

12 December 2020

Low molecular weight versus unfractionated heparin. A clinical and economic appraisal

1 reference

12 December 2020

Oral anticoagulant drugs

1 reference

12 December 2020

Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis

1 reference

12 December 2020

Assessment of outpatient treatment of deep-vein thrombosis with low-molecular-weight heparin

1 reference

12 December 2020

Replacing inpatient care by outpatient care in the treatment of deep venous thrombosis--an economic evaluation. TASMAN Study Group

1 reference

12 December 2020

Low molecular weight heparin

1 reference

12 December 2020

Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis

1 reference

12 December 2020

A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism.

1 reference

12 December 2020

Subcutaneous heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin

1 reference

12 December 2020

Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials

1 reference

12 December 2020

10.2165/00019053-200220090-00003

Identifiers

DOI

1 reference

14 May 2018

Dimensions Publication ID

0 references

1 reference

14 May 2018